Objectives: This study aimed to investigate the safety and therapeutic efficacy of herbal drug, Di Huang Yin Zi (DHYZ), in patients affected by ischemic stroke.
Methods: In this double blind, placebo-controlled study, a total of 100 patients with recent (less than 30 days) ischemic stroke were randomized to receive DHYZ or placebo for 12 weeks. Both groups also received rehabilitation therapy during the study period. As there were 13 dropouts, a total of 45 patients on DHYZ and 42 on placebo were available for analysis. The Fugl-Meyer Assessment (FMA) and Barthel index (BI) were assessed before treatment and at 4-week intervals.
Results: We observed that the FMA score and BI were increased, in both groups at week 4, 8 and 12 compared with the baseline. Furthermore, significantly better FMA score was observed in patients treated with DHYZ at week 8 and 12 (both P<0.05). BI was significantly higher in DHYZ group than in placebo group at weeks 12 (P<0.05). At week 12, the 95% Confidence Intervals (CI) of mean difference of FMA and BI also indicated that the differences between two groups were statistically significant. Compared to placebo, DHYZ produced significantly greater improvement in FMA grade at week 12 (44.4% versus 23.8%, χ(2)=4.09, P<0.05).
Conclusions: DHYZ showed good efficacy, safety and tolerability in patients affected by ischemic stroke. We conclude that DHYZ may be a useful therapeutic option in patients with ischemic stroke.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctim.2015.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dihuang Yinzi, a Classical Chinese Herbal Prescription, for Amyotrophic Lateral Sclerosis: A 12-Year Follow-up Case Report.
Medicine (Baltimore)
April 2016
From the Department of Internal Medicine of TCM, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou (HQ); Department of Neurology, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou (J-hL, S-bY, J-qK, G-qZ); and Department of Neurology, Zhejiang Provincial Hospital of TCM, the First Affiliated Hospital of Zhejiang Chinese Medical University (C-lQ), Hangzhou, China.
Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease with no effective treatment and death within 2 to 5 years after symptom onset. Here, we reported a case of ALS patient using modified Dihuang Yinzi (DHYZ), a classical traditional Chinese medicine (TCM) prescription, who has survived 12 years with significant improvement in bulbar paralysis.A 41-year-old Chinese Han nationality woman was admitted to the hospital with complaints of weakened bilateral grip, slurred speech, stumbling, and muscle twitching for 3 years.
View Article and Find Full Text PDFCombined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia.
Neurosci Lett
October 2015
Department of Neurology, Longhua Hospital of Traditional Chinese Medicine University, Shanghai 200032, China.
Here we conducted a randomized and double-blind study attempting to explore the safety and efficacy of combined therapy of Di-Huang-Yi-Zhi (DHYZ) with donepezil in treating Parkinson's disease dementia (PDD). Sixty PDD patients were included and randomly divided into control group and DHYZ group. All patients were given donepezil (5 mg last for a month, then 10 mg for the rest months, once daily), while patients in DHYZ group were additionally administrated with DHYZ (150 ml, twice daily).
View Article and Find Full Text PDFThe beneficial effects of the herbal medicine Di-huang-yin-zi (DHYZ) on patients with ischemic stroke: A Randomized, Placebo controlled clinical study.
Complement Ther Med
August 2015
Department of Surgery, University of California, Davis, Sacramento, CA 95817, USA.
Objectives: This study aimed to investigate the safety and therapeutic efficacy of herbal drug, Di Huang Yin Zi (DHYZ), in patients affected by ischemic stroke.
Methods: In this double blind, placebo-controlled study, a total of 100 patients with recent (less than 30 days) ischemic stroke were randomized to receive DHYZ or placebo for 12 weeks. Both groups also received rehabilitation therapy during the study period.
Objective: This study investigated the safety and therapeutic efficacy of Di Huang Yin Zi (DHYZ), a traditional Chinese decoction used to treat neurological disorders, in spinal cord injury (SCI).
Methods: In this double-blind, placebo-controlled study, patients with traumatic SCI and American Spinal Injury Association (ASIA) impairment grades B-D were randomized to receive DHYZ (n = 30) or placebo (n = 30) for 12 weeks. Both groups also received rehabilitation therapy during the study period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!